1H-indole-5-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide | 1357582-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1H-indole-5-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide
• 英文别名: 1H-Indole-5-carboxylic acid[3-(1H-tetrazol-5-yl)-phenyl]-amide；N-[3-(2H-tetrazol-5-yl)phenyl]-1H-indole-5-carboxamide
• CAS: 1357582-04-7
• 化学式: C₁₆H₁₂N₆O
• 分子量: 304.311
• InChiKey: UASRDAZJFYRGBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(3-氨基苯基)四唑 、 吲哚-5-羧酸 以to afford the title compound in 9% yield的产率得到1H-indole-5-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide
  参考文献：
  名称：

  COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT

  摘要：

  本公开的实施例在某些方面涉及β-内酰胺酶抑制剂、包括β-内酰胺酶抑制剂的制药组合物、治疗病症（例如感染）或疾病的方法、使用组合物或制药组合物的治疗方法等。

  公开号：

  US20140378516A1

文献信息

• COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT
  申请人：University of South Florida

  公开号：US20140378516A1

  公开（公告）日：2014-12-25

  Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

  本公开的实施例在某些方面涉及β-内酰胺酶抑制剂、包括β-内酰胺酶抑制剂的制药组合物、治疗病症（例如感染）或疾病的方法、使用组合物或制药组合物的治疗方法等。
• US9556131B2
  申请人：——

  公开号：US9556131B2

  公开（公告）日：2017-01-31
• Structure-Based Design of Potent and Ligand-Efficient Inhibitors of CTX-M Class A β-Lactamase
  作者：Derek A. Nichols、Priyadarshini Jaishankar、Wayne Larson、Emmanuel Smith、Guoqing Liu、Racha Beyrouthy、Richard Bonnet、Adam R. Renslo、Yu Chen

  DOI：10.1021/jm2014138

  日期：2012.3.8

  The emergence of CTX-M class A extended-spectrum beta-lactamases poses a serious health threat to the public. We have applied structure-based design to improve the potency of a novel noncovalent tetrazole-containing CTX-M inhibitor (K-i = 21 mu M) more than 200-fold via structural modifications targeting two binding hot spots, a hydrophobic shelf formed by Pro167 and a polar site anchored by Asp240. Functional groups contacting each binding hot spot independently in initial designs were later combined to produce analogues with submicromolar potencies, including 6-trifluoromethyl-3H-benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide, which had a K-i value of 89 nM and reduced the MIC of cefotaxime by 64-fold in CTX-M-9 expressing Escherichia coli. The in vitro potency gains were accompanied by improvements in ligand efficiency (from 0.30 to 0.39) and LipE (from 1.37 to 3.86). These new analogues represent the first nM-affinity noncovalent inhibitors of a class A beta-lactamase. Their complex crystal structures provide valuable information about ligand binding for future inhibitor design.